June is going to be a big month for biotech IPOs
Nine biopharma companies have already gone public this month, raising more than $3 billion in the process, and there’s another seven slated to pull off debut offerings before June is over.
If everything works out, they’ll raise about $700 million combined. And the performance of their forebears bodes well. Of the nine companies that have gone public this month, all have sold shares either above or at the top of their proposed price ranges. Royalty Pharma made headlines with its record-breaking IPO, but the smaller likes of Vaxcyte, Burning Rock Biotech, and Avidity Biosciences also increased in value after pricing.
The next likely debutante is Forma Therapeutics, a hematology company expected to raise about $200 million in an IPO this week.
If everything works out, they’ll raise about $700 million combined. And the performance of their forebears bodes well. Of the nine companies that have gone public this month, all have sold shares either above or at the top of their proposed price ranges. Royalty Pharma made headlines with its record-breaking IPO, but the smaller likes of Vaxcyte, Burning Rock Biotech, and Avidity Biosciences also increased in value after pricing.
The next likely debutante is Forma Therapeutics, a hematology company expected to raise about $200 million in an IPO this week.
.png)
No hay comentarios:
Publicar un comentario